

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**Sisram Medical Ltd**  
**復銳醫療科技有限公司\***  
*(Incorporated in Israel with limited liability)*  
**(Stock Code: 1696)**

**INSIDE INFORMATION ANNOUNCEMENT**

This announcement is made by Sisram Medical Ltd 復銳醫療科技有限公司\* (the “**Company**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Company for the six months ended June 30, 2020 (the “**Period**”) and the information currently available to the Board, the revenue of the Company for the Period is expected to decrease by approximately 16%, the Company’s profit for the Period (the “**Profit**”) is expected to decrease by approximately 58% and the Company’s Adjusted Net Profit<sup>Note 1</sup> for the Period is expected to decrease by approximately 47%, in each case as compared to the same period in 2019. The decrease in the Profit is mainly attributable to the outbreak of the COVID-19 pandemic which has had a significant impact on the global medical aesthetics industry.

While the Board considers it prudent to draw the attention of the Shareholders and potential investors of the Company to this information, the current fundamentals of the Company remains healthy and the Company has sufficient funds to meet its future business needs. The lower Profit for the Period reflected the Company’s decision to prioritize the use of its resources to maintain its ongoing operations with minimal cut backs in order to maintain its flexibility and resilience capabilities. Following the first signs of recovery in market demand in June 2020, the Company is further enhancing its competitive position by expanding its scope of business and maintaining continuous and stable development of its business.

The Board reminds Shareholders and potential investors that the information contained in this announcement is only based on the preliminary assessment made by the Company with reference to the information available to the Board as at the date of this announcement, and has not been reviewed or audited by the independent auditor or the audit committee of the Company. The actual results of the Company for the Period may differ from the information contained in this announcement. Detailed financial information of the Company will be disclosed in the unaudited interim results announcement of the Company for the Period, which is expected to be published by the end of August 2020.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

*Note 1: The Company calculates adjusted net profit by taking profit for the period and adjusting: (i) amortization of other intangible assets arising from acquisition of subsidiaries; (ii) changes in contingent consideration arising from the acquisition of Nova Medical Israel Ltd.; (iii) bonus to managements and employees as a result of the completion of the listing of the Company on the Hong Kong Stock Exchange; (iv) due diligence; and (v) deferred tax liability arising from other intangible assets, which primarily relates acquisitions.*

On Behalf of the Board  
**Sisram Medical Ltd**  
復銳醫療科技有限公司\*  
**Yi LIU**  
Chairman

Hong Kong, July 16, 2020

*As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yi LIU, Mr. Lior Moshe DAYAN and Mr. Guojun BU as Executive Directors; Mr. Yifang WU and Mr. Yao WANG as Non-Executive Directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as Independent Non-executive Directors.*

\* for identification purpose only